TABLE 3.
In vitro IC50 values and ring-stage survival of culture-adapted P. falciparum from day 3 parasite-positive and -negative patients
| Druga | Parasite positive (n = 19) |
Parasite negative (n = 25) |
P valueb | Total (n = 44) |
3D7 (mean) | P valuec | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median (IQR) | Mean (95% CI) | Range | Median (IQR) | Mean (95% CI) | Range | Median (IQR) | Mean (95% CI) | Range | ||||
| DHARSA | 5.0 (2.2–7.7) | 1.0–19.8 | 0.5 (0–1.9) | 0–61.1 | <0.0001 | 2.0 (0.1–6.1) | 0–61.1 | 0 | <0.0001 | |||
| ATS | 1.6 (1.2–2.2) | 1.1–4.8 | 2.3 (1.6–3.2) | 1.1–6.3 | 0.0155 | 1.8 (1.4–2.8) | 1.1–6.3 | 1.7 | 0.0040 | |||
| DHA | 2.2 (1.8–3.0) | 0.8–6.4 | 2.1 (1.6–2.7) | 1.1–3.6 | 0.3996 | 2.2 (1.6–2.8) | 0.8–6.4 | 1.5 | <0.0001 | |||
| PND | 9.1 (7.0–11.8) | 4.5–34.8 | 7.2 (6.0–8.4) | 5.1–14.5 | 0.0642 | 7.6 (6.3–9.8) | 4.5–34.8 | 4.1 | <0.0001 | |||
| CQ | 1,567.0 (1,155.0–1,980.0) | 478.8–3,278.0 | 1,606.0 (1,118.0–2,094.0) | 296.2–4,097.0 | 0.6386 | 1,589.0 (1,277.0–1,901.0) | 296.2–4,097 | 17.6 | <0.0001 | |||
| PPQ | 23.8 (18.9–28.8) | 8.9–46.4 | 20.0 (17.3–22.7) | 10.5–34.5 | 0.1305 | 21.7 (19.1–24.3) | 8.9–46.4 | 14.7 | <0.0001 | |||
| MQ | 34.1 (21.5–46.7) | 2.0–93.8 | 23.0 (19.0–27.0) | 7.1–44.7 | 0.2346 | 28.0 (22.0–34.0) | 2.0–93.8 | 17.2 | 0.0008 | |||
| QN | 47.2 (38.4–55.9) | 21.1–79.2 | 85.1 (57.0–113.2) | 28.3–207.2 | 0.0563 | 68.1 (51.5–84.7) | 21.1–207.2 | 15.1 | <0.0001 | |||
| LMF | 4.8 (3.0–6.6) | 1.4–12.5 | 9.0 (6.4–11.6) | 1.4–19.6 | 0.0247 | 7.1 (5.4–8.8) | 1.4–19.6 | 5.2 | 0.0310 | |||
a
DHARSA was performed by exposing tightly synchronized young ring-stage parasites (0 to 3 h) to a bolus DHA treatment for 6 h and measuring parasite survival (as percentages) 66 h later. The rest of the assays measuring IC50 values (in nM) were the standard drug assay where parasites were exposed to continuous drugs for 72 h, and parasite growth was measured by SYBR green I fluorescence.
b
Mann-Whitney U test.
c
Student's t test.